Antibody conjugation and formulation

Research output: Contribution to journalReview article

Abstract

In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates, more accessible routes of administration such as intramuscular and subcutaneous are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of ADCs and the demands of formulation for high concentration clinical implementation.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalAntibody Therapeutics
Volume1
Issue number1
DOIs
StatePublished - Jun 1 2018

Fingerprint

Antibodies
Intravenous Infusions
Viscosity
Pharmaceutical Preparations
Monoclonal Antibodies

Keywords

  • Antibody-drug conjugates
  • Conjugation
  • Formulation
  • High concentration
  • Site-specific

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Antibody conjugation and formulation. / Alves, Nathan J.

In: Antibody Therapeutics, Vol. 1, No. 1, 01.06.2018, p. 33-39.

Research output: Contribution to journalReview article

@article{05f1e455743a4ba0b7a72b4a7dd952f0,
title = "Antibody conjugation and formulation",
abstract = "In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates, more accessible routes of administration such as intramuscular and subcutaneous are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of ADCs and the demands of formulation for high concentration clinical implementation.",
keywords = "Antibody-drug conjugates, Conjugation, Formulation, High concentration, Site-specific",
author = "Alves, {Nathan J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/abt/tbz002",
language = "English (US)",
volume = "1",
pages = "33--39",
journal = "Antibody Therapeutics",
issn = "2516-4236",
number = "1",

}

TY - JOUR

T1 - Antibody conjugation and formulation

AU - Alves, Nathan J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates, more accessible routes of administration such as intramuscular and subcutaneous are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of ADCs and the demands of formulation for high concentration clinical implementation.

AB - In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates, more accessible routes of administration such as intramuscular and subcutaneous are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of ADCs and the demands of formulation for high concentration clinical implementation.

KW - Antibody-drug conjugates

KW - Conjugation

KW - Formulation

KW - High concentration

KW - Site-specific

UR - http://www.scopus.com/inward/record.url?scp=85077768507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077768507&partnerID=8YFLogxK

U2 - 10.1093/abt/tbz002

DO - 10.1093/abt/tbz002

M3 - Review article

AN - SCOPUS:85077768507

VL - 1

SP - 33

EP - 39

JO - Antibody Therapeutics

JF - Antibody Therapeutics

SN - 2516-4236

IS - 1

ER -